These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23613418)

  • 1. Triple negative endometrial cancer may be more sensitive to platinum based chemotherapy.
    Altundag O; Dursun P; Roach EC; Altundag K
    J BUON; 2013; 18(1):289. PubMed ID: 23613418
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
    Ellis MJ
    J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmaceutical therapy of breast cancer].
    Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
    Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
    [No Abstract]   [Full Text] [Related]  

  • 4. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
    Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
    Huober J; von Minckwitz G; Denkert C; Tesch H; Weiss E; Zahm DM; Belau A; Khandan F; Hauschild M; Thomssen C; Högel B; Darb-Esfahani S; Mehta K; Loibl S
    Breast Cancer Res Treat; 2010 Nov; 124(1):133-40. PubMed ID: 20697801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmenopausal hormone receptor-positive advanced breast cancer.
    Connolly RM; Stearns V
    Oncology (Williston Park); 2013 Jun; 27(6):571-2, 574, 576 passim. PubMed ID: 23909072
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical and morphological features and treatment for lobular breast cancer].
    Tabagua TT; Semiglazov VV; Bus'ko EA; Semiglazova TIu; Voroshnikov VV
    Vopr Onkol; 2013; 59(3):386-9. PubMed ID: 23909043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation between receptor status and results of treatment in endometrial carcinoma].
    Baĭnazarova AA; Iskakova ZhK
    Vopr Onkol; 2006; 52(6):654-8. PubMed ID: 17338243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
    Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
    Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers?
    Pignol JP; Rakovitch E; Olivotto IA
    J Clin Oncol; 2011 Jul; 29(21):2841-3. PubMed ID: 21670459
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.
    Parissenti AM; Chapman JA; Kahn HJ; Guo B; Han L; O'Brien P; Clemons MP; Jong R; Dent R; Fitzgerald B; Pritchard KI; Shepherd LE; Trudeau ME
    Breast Cancer Res Treat; 2010 Jan; 119(2):347-56. PubMed ID: 19771508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
    Gómez HL; Pinto JA; Olivera M; Vidaurre T; Doimi FD; Vigil CE; Velarde RG; Abugattas JE; Alarcón E; Vallejos CS
    Breast; 2011 Feb; 20(1):39-45. PubMed ID: 20705464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
    J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1 expression in triple negative breast carcinoma: the paradox revisited.
    Sidoni A; Cartaginese F; Colozza M; Gori S; Crinó L
    Breast Cancer Res Treat; 2008 Oct; 111(3):569-70. PubMed ID: 17987380
    [No Abstract]   [Full Text] [Related]  

  • 18. [Immunologic differences of triple-negative and luminal A breast cancer].
    Mel'nikov DIu; Pushina IV; Lagereva IuG; Beĭkin IaB; Ivanova IIu
    Vopr Onkol; 2013; 59(3):390-2. PubMed ID: 23909044
    [No Abstract]   [Full Text] [Related]  

  • 19. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
    Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U
    Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
    Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
    Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.